Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, People's Republic of China.
Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, People's Republic of China.
Emerg Microbes Infect. 2022 Dec;11(1):2304-2314. doi: 10.1080/22221751.2022.2114854.
Data regarding protection against mortality and severe complications after Omicron BA.2 infection with CoronaVac and BNT162b2 vaccines remains limited. We conducted a case-control study to evaluate the risk of severe complications and mortality following 1-3 doses of CoronaVac and BNT162b2 using electronic health records database. Cases were adults with their first COVID-19-related mortality or severe complications between 1 January and 31 March 2022, matched with up-to 10 controls by age, sex, index date, and Charlson Comorbidity Index. Vaccine effectiveness against COVID-19-related mortality and severe complications by type and number of doses was estimated using conditional logistic regression adjusted for comorbidities and medications. Vaccine effectiveness (95% CI) against COVID-19-related mortality after two doses of BNT162b2 and CoronaVac were 90.7% (88.6-92.3) and 74.8% (72.5-76.9) in those aged ≥65, 87.6% (81.4-91.8) and 80.7% (72.8-86.3) in those aged 50-64, 86.6% (71.0-93.8) and 82.7% (56.5-93.1) in those aged 18-50. Vaccine effectiveness against severe complications after two doses of BNT162b2 and CoronaVac were 82.1% (74.6-87.3) and 58.9% (50.3-66.1) in those aged ≥65, 83.0% (69.6-90.5) and 67.1% (47.1-79.6) in those aged 50-64, 78.3% (60.8-88.0) and 77.8% (49.6-90.2) in those aged 18-50. Further risk reduction with the third dose was observed especially in those aged ≥65 years, with vaccine effectiveness of 98.0% (96.5-98.9) for BNT162b2 and 95.5% (93.7-96.8) for CoronaVac against mortality, 90.8% (83.4-94.9) and 88.0% (80.8-92.5) against severe complications. Both CoronaVac and BNT162b2 vaccination were effective against COVID-19-related mortality and severe complications amidst the Omicron BA.2 pandemic, and risks decreased further with the third dose.
关于科兴和国药疫苗对奥密克戎 BA.2 感染后预防死亡和严重并发症的保护作用的数据仍然有限。我们使用电子健康记录数据库进行了一项病例对照研究，以评估 1-3 剂科兴和国药疫苗对严重并发症和死亡率的风险。病例为 2022 年 1 月 1 日至 3 月 31 日期间首次与 COVID-19 相关的死亡或严重并发症的成年人，按年龄、性别、索引日期和 Charlson 合并症指数与最多 10 名对照匹配。使用条件逻辑回归调整合并症和药物后，估计了两种和三种剂量的 COVID-19 相关死亡率和严重并发症的疫苗有效性。在≥65 岁的人群中，两剂 BNT162b2 和科兴疫苗对 COVID-19 相关死亡率的疫苗有效性分别为 90.7%（88.6-92.3）和 74.8%（72.5-76.9），在 50-64 岁的人群中为 87.6%（81.4-91.8）和 80.7%（72.8-86.3），在 18-50 岁的人群中为 86.6%（71.0-93.8）和 82.7%（56.5-93.1）。在≥65 岁的人群中，两剂 BNT162b2 和科兴疫苗对严重并发症的疫苗有效性分别为 82.1%（74.6-87.3）和 58.9%（50.3-66.1），在 50-64 岁的人群中为 83.0%（69.6-90.5）和 67.1%（47.1-79.6），在 18-50 岁的人群中为 78.3%（60.8-88.0）和 77.8%（49.6-90.2）。在≥65 岁的人群中，尤其是在接种第三剂疫苗后，观察到进一步降低风险的趋势，BNT162b2 和科兴疫苗对死亡率的有效性分别为 98.0%（96.5-98.9）和 95.5%（93.7-96.8），对严重并发症的有效性分别为 90.8%（83.4-94.9）和 88.0%（80.8-92.5）。科兴和国药疫苗在奥密克戎 BA.2 大流行期间对 COVID-19 相关死亡和严重并发症均有效，且第三剂接种可进一步降低风险。
